Olivier Brandicourt, chief executive of French pharma major Sanofi, announced today a number of changes to the company's executive committee. 23 May 2016
Keith Thompson, the chief executive of the Cell and Gene Therapy Catapult (CGT), tells The Pharma Letter's Guy Martin that the launch of Islexa UK, a company aimed at bringing islet transplant therapy to thousands of diabetes patients, is evidence of the very real difference this new field of medicine can make to patients’ lives in the near future. 23 May 2016
It goes without saying that being successful in pharma requires innovation, particularly with a number of big companies facing damaging patent expirations in the next year or two. 23 May 2016
Top executives from pharma and biotech companies across the globe are gearing up for one of the industry’s most prestigious annual events. The 2016 annual meeting of the American Society of Clinical Oncology (ASCO) will bring together some thirty thousand professionals from around the world to discuss the latest research and advances in cancer care. 23 May 2016
UK-based Proteome Sciences has said that Jeremy Haigh will be joining its board of directors as chief executive in June (subject to regulatory approval). 18 May 2016
Novartis late yesterday announced major changes to focus its Pharmaceuticals Division by creating two business units reporting to the chief executive: Novartis Pharmaceuticals and Novartis Oncology. 18 May 2016
In our weekly expert view piece, Michael Jewell, healthcare partner at Cavendish Corporate Finance, examines a recent surge in M&A and questions whether it signals more activity later in 2016. 17 May 2016
Japanese pharma major Takeda Pharmaceutical has appointed James Kehoe as its new chief financial officer (CFO), hailing his ‘passion for transforming large organizations’ as key to the company’s growth ambitions. 16 May 2016
Pharma’s increasing early engagement with small biotechs has been one of the themes of the industry in the last decade as companies prepare for a shift towards personalized medicines. The Pharma Letter's Guy Martin has explored the issue, asking how far and wide pharma’s engagement with independent molecular biologists has gone. 16 May 2016
Following news this week that Cardiff-based cell therapy company Cell Therapy Ltd has signed a partnership agreement giving Japan’s Daiichi Sankyo the rights to its heart failure drug Heartcel, the company’s chief executive, Ajan Reginald, spoke to TPL’s Katie Osborne about the decision. 11 May 2016
In our weekly expert view piece Dr Nick Meyers, programme director at Boyd Consultants examines the implications what the regulatory and legislative landscape in the biopharmaceutical industry could look like post-Brexit. 10 May 2016
Achieving commercial success and leading new innovations at the same time as proving your credentials as ethical, patient-focused and community-minded is what so many big pharma companies are striving for. 9 May 2016
Stephen O’Hara is chief executive of OptiBiotix Health, a UK-based biotech which has been interesting big pharma recently with its Lactobacillus plantarum strain, a statin-free cholesterol pill. He spoke to the Pharma Letter... 4 May 2016
In our weekly expert view piece Ed Corbett, engagement manager at Novasecta, questions whether UK pharma giant GlaxoSmithKline has the right strategy in place to sustain future growth. 3 May 2016
The Russian government is considering subsidizing the production of cheap drugs, amid the fears of their disappearance from the market, according to recent statements of Arkady Dvorkovich, Russia’s Deputy Prime Minister, reports The Pharma Letter’s local correspondent. 2 May 2016
Japanese drug major Astellas has appointed Rodrigo Fernandez executive director, international business, with responsibility for managing business in Latin America outside of Brazil. 29 April 2016
Ireland-based Perrigo has announced that Sharon Kochan will lead the expansion of the company’s branded consumer healthcare (BCH) segment. 28 April 2016
US biotech major Biogen has lured Michael Ehlers, a senior vice president at pharma giant Pfizer, as its executive vice president, Research and Development. 27 April 2016
Oligonucleotide therapeutics are rapidly emerging as a promising class of drugs capable of addressing a variety of genetic and complex diseases by targeting RNA sequences.1 16 September 2024
The protection of intellectual property (IP) rights of foreign pharmaceutical companies in Russia remains complex situation, according to recent statements by Konstantin Panurovsky, legal director of AstraZeneca’s Russian subsidiary, reports The Pharma Letter’s local correspondent. 13 September 2024
The Russian Ministry of Health wants to speed registration of drugs that are not localized in the Russian Federation at the time of the application submitted by domestic pharmaceutical companies, explaining such changes by "unpredictable geopolitical situation," reports The Pharma Letter’s local correspondent. 12 September 2024
NewCo, a relatively new business model that involves a joint venture (JV) between a biotech and a group of investors to bring the biotech’s promising assets to the global market, is gaining popularity among Chinese biotechs, who traditionally rely on out-licensing deals to capitalize assets, s 11 September 2024
The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer. 10 September 2024
A significant drop has been noticed in the prices of active pharmaceutical ingredients (APIs), bringing much-needed relief to the pharmaceutical industry and potentially translating to lower drug costs for consumers. 9 September 2024
Amid an explosion in investment and development milestones seen over the past decade, the age of radiopharmaceuticals as both diagnostics and as therapeutics is very much arriving. 5 September 2024
German pharma major Bayer has filed a lawsuit against the Russian drugmaker Promomed to protect the patent rights for Xarelto (rivaroxaban), its treatment for stroke prevention which is the best-selling drug in the Russian market at present, The Pharma Letter’s local correspondent reports. 2 September 2024
In a major crackdown, the Indian government has imposed an immediate ban on 156 fixed-dose combination (FDC) drugs, including commonly used antibiotics, pain relievers,and multivitamins. 27 August 2024
Russia plans to create conditions for a significant increase of domestic production of anti-Rhesus immunoglobulin drugs after a sharp decrease of their imports to the local market this year, reports The Pharma Letter’s local correspondent. 22 August 2024
Accord Healthcare might not be as well-known as certain preeminent pharma corporations in the UK and Europe, but you would struggle to find any company making a greater contribution to the production and supply of medicines across the continent. 14 August 2024
The shortage of drugs in Russia is deepening, and is currently being observed in almost 70 regions throughout the country and forcing the local state to consider ways to resume stable supplies to local market, reports The Pharma Letter’s local correspondent. 13 August 2024
US biotech major Biogen is disputing the launch of a Russian generic of Spinraza (nusinersen), a drug, which is used to treat spinal muscular atrophy (SMA), reports The Pharma Letter’s local correspondent. 7 August 2024
CytoReason’s $80 million venture round may not have been the biggest in July, but it is one of a growing number of investor bets on AI powered drug discovery this year. 7 August 2024
Domestic drugs and foreign drugs, the production of which is localized in Russia, will be given a priority when included in the list of vital and essential drugs (VED) and expensive drugs, according to a recent resolution signed by the Russian government, The Pharma Letter’s local correspondent reports. 1 August 2024